American Society of Gene & Cell Therapy
Postdoctoral Fellowship
American Society of Gene & Cell Therapy, Boston, Massachusetts, us, 02298
Postdoctoral Positions
are available on inner ear regeneration and gene therapy for hearing loss.We are leading multiple groundbreaking projects focused on hearing restoration, encompassing both the regeneration of various inner ear cell types and gene therapy for genetic hearing loss. Our work includes:Regeneration of Inner Ear Cells : We target the regeneration of diverse cell types, including hair cells, neurons, and other supporting cells, in adult animal models (mice and pigs). Our approach leverages Myc/Notch co-activation for reprogramming (Shu et al., Nat Commun, 2019), complemented by a drug-like cocktail we've developed that successfully induces hair cell regeneration in the adult cochlea in vivo (Quan et al., PNAS, 2023). Furthermore, we've identified critical molecules that enhance ganglion neurite outgrowth and synapse regeneration, paving the way for treating “hidden hearing loss” caused by synaptopathy.Gene and Editing Therapy : We are working on various deaf mouse models with the aim of restoring hearing in adults and advancing our findings toward clinical application. Our gene and editing therapies have successfully restored hearing in multiple mouse models (Du et al., Mol Ther, 2023; Yong et al., Nat Commun, 2023; Zhu et al., Sci Transl Med, 2024), with some now in the IND-enabling study phase.Our laboratory employs state-of-the-art technologies, including in vitro adult cochlea explant culture, reprogramming, scRNAseq, genome editing, AAV delivery, nanoparticle delivery, and physiological function analysis.We are pioneers in clinical applications, having conducted the first successful OTOF gene therapy trial in children born with complete hearing loss, resulting in restored hearing and speech capabilities (Lv et al., The Lancet, 2024; Wang et al., Nat Med, 2024).Our lab is part of Eaton-Peabody Laboratories, the largest hearing research center globally, renowned for its diverse research programs. We offer a unique and exciting opportunity for candidates interested in advancing basic research to translational applications, including human studies.Candidate Requirements : We seek individuals with a Ph.D., M.D./Ph.D., or M.D. with a robust background in molecular biology, cellular biology, genetics, gene editing, RNAseq, and animal models. A strong track record of scientific publications is essential.
#J-18808-Ljbffr
are available on inner ear regeneration and gene therapy for hearing loss.We are leading multiple groundbreaking projects focused on hearing restoration, encompassing both the regeneration of various inner ear cell types and gene therapy for genetic hearing loss. Our work includes:Regeneration of Inner Ear Cells : We target the regeneration of diverse cell types, including hair cells, neurons, and other supporting cells, in adult animal models (mice and pigs). Our approach leverages Myc/Notch co-activation for reprogramming (Shu et al., Nat Commun, 2019), complemented by a drug-like cocktail we've developed that successfully induces hair cell regeneration in the adult cochlea in vivo (Quan et al., PNAS, 2023). Furthermore, we've identified critical molecules that enhance ganglion neurite outgrowth and synapse regeneration, paving the way for treating “hidden hearing loss” caused by synaptopathy.Gene and Editing Therapy : We are working on various deaf mouse models with the aim of restoring hearing in adults and advancing our findings toward clinical application. Our gene and editing therapies have successfully restored hearing in multiple mouse models (Du et al., Mol Ther, 2023; Yong et al., Nat Commun, 2023; Zhu et al., Sci Transl Med, 2024), with some now in the IND-enabling study phase.Our laboratory employs state-of-the-art technologies, including in vitro adult cochlea explant culture, reprogramming, scRNAseq, genome editing, AAV delivery, nanoparticle delivery, and physiological function analysis.We are pioneers in clinical applications, having conducted the first successful OTOF gene therapy trial in children born with complete hearing loss, resulting in restored hearing and speech capabilities (Lv et al., The Lancet, 2024; Wang et al., Nat Med, 2024).Our lab is part of Eaton-Peabody Laboratories, the largest hearing research center globally, renowned for its diverse research programs. We offer a unique and exciting opportunity for candidates interested in advancing basic research to translational applications, including human studies.Candidate Requirements : We seek individuals with a Ph.D., M.D./Ph.D., or M.D. with a robust background in molecular biology, cellular biology, genetics, gene editing, RNAseq, and animal models. A strong track record of scientific publications is essential.
#J-18808-Ljbffr